AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16824559 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (10 individuals)
Number of subjects: 18
Study 14718419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry absorbent dressing (Primapore)
Number of subjects: 737
Study 14718419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing (Duoderm Thin)
Number of subjects: 737
Study 14718419 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroactive dressing (Opsite)
Number of subjects: 737
Study 14718419 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 737
Study 12872566 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopic surgery
Number of subjects: 25
Study 12872566 — intervention group
Group type: COMPARATOR
Intervention: Traditional laparoscopic approach
Number of subjects: 25
Study 10197660 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1829
Study 10197660 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study 8541635 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506 and prednisolone (FK)
Number of subjects: 121
Study 8541635 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine, prednisolone, azathioprine, and rabbit antithymocyte globulin (CsA)
Number of subjects: 121
Study 2313465 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA test with monoclonal antibodies against E. histolytica antigen
Number of subjects: 150
Study 2313465 — intervention group
Group type: COMPARATOR
Intervention: Standard diagnostic methods (OBP and rectosigmoidoscopy)
Number of subjects: 150
Study 7412226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids with progressively extended low-frequency emphasis
Number of subjects: 12
Study 7412226 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids with low-cutoff frequency settings
Number of subjects: 12
Study 7412226 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired-comparison format
Number of subjects: 12
Study 31496453 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital photographic portion-size estimation aids (PSEA)
Number of subjects: 300
Study 31496453 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual-food PSEA
Number of subjects: 300
Study 31496453 — intervention group
Group type: COMPARATOR
Intervention: Weighed meal record
Number of subjects: 300
Study 29339527 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone every 2 weeks for 22 weeks
Number of subjects: 32
Study 29339527 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) every 2 weeks for 22 weeks
Number of subjects: 32
Study 26901417 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric liaison intervention (preoperative consultation, individual treatment plan, daily visits by a geriatric nurse)
Number of subjects: 260
Study 26901417 — intervention group
Group type: COMPARATOR
Intervention: Postoperative delirium
Number of subjects: 260
Study 24476782 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) protocol with traditional strength training
Number of subjects: 62
Study 24476782 — intervention group
Group type: COMPARATOR
Intervention: Traditional upper- and lower-body split strength program without BFR
Number of subjects: 62
Study 22678875 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygium resection combined with conjunctival autograft
Number of subjects: 118
Study 22678875 — intervention group
Group type: COMPARATOR
Intervention: Pterygium resection combined with amniotic membrane transplantation
Number of subjects: 118
Study 20622670 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal cross-linking (CXL)
Number of subjects: 40
Study 20622670 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin 0.1% eyedrops for 1 month of topical use
Number of subjects: 40
Study 17430602 — intervention group
Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 95
Study 17430602 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 95
Study 15936175 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG), mean daily dose of 250 mg
Number of subjects: 20
Study 15936175 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate (VPA), mean daily dose of 2070 mg
Number of subjects: 20
Study 12085156 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg once daily
Number of subjects: 1456
Study 12085156 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once a week
Number of subjects: 1456
Study 12085156 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 50 mg once a week
Number of subjects: 1456
Study 9501262 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose fentanyl anesthesia (50 microg/kg with diazepam 0.1 mg/kg for induction, maintained with fentanyl 2 microg/kg/hr and diazepam 0.05 mg/kg/hr)
Number of subjects: 50
Study 9501262 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone anesthesia (7 mg/kg for induction, maintained with enflurane 0.7‐1.5% and thiopentone 3 mg/kg/hr during CPB)
Number of subjects: 50
Study 8580271 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s., Metronidazole 400 mg t.d.s. for 14 days
Number of subjects: 119
Study 8580271 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg daily, Amoxycillin 500 mg t.d.s. and placebo for 14 days
Number of subjects: 119
Study 29266180 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml of 0.4% dexamethasone added to 18 ml 0.5% bupivacaine‐epinephrine
Number of subjects: 56
Study 29266180 — intervention group
Group type: COMPARATOR
Intervention: 2 ml 0.9% normal saline added to 18 ml 0.5% bupivacaine‐epinephrine
Number of subjects: 56
Study 27206636 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume centers (HVCs)
Number of subjects: 495
Study 27206636 — intervention group
Group type: COMPARATOR
Intervention: Low-volume centers (LVCs)
Number of subjects: 495
Study 25711952 — intervention group
Group type: EXPERIMENTAL
Intervention: ISIS-CRPRx
Number of subjects: 7
Study 23043368 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO 5825 (0.1, 0.3, 1.0, 3.0, or 10 mg kg(‐1) i.v. or 3.0 mg kg(‐1) s.c.)
Number of subjects: 64
Study 23043368 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO 5825 (10 mg kg(‐1) i.v.) in healthy atopic subjects
Number of subjects: 64
Study 23043368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21127156 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic E. coli strain Nissle 1917 (Mutaflor), administered at a daily dose of 5×10(9)‐5×10(10) bacteria, twice daily.
Number of subjects: 69
Study 21127156 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 69
Study 18781073 — intervention group
Group type: EXPERIMENTAL
Intervention: Yacon syrup (20 g daily, equal to 6.4 g FOS)
Number of subjects: 16
Study 16438769 — intervention group
Group type: EXPERIMENTAL
Intervention: Infero-nasal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Number of subjects: 100
Study 16438769 — intervention group
Group type: EXPERIMENTAL
Intervention: Infero-temporal sub-Tenon's injection of lidocaine 2% with hyaluronidase 15 IU mL‐1
Number of subjects: 100
Study 12492739 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (proton pump inhibitor plus amoxicillin and clarithromycin for 1 week)
Number of subjects: 120
Study 12492739 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor alone for 8 weeks
Number of subjects: 120
Study 12492739 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (for ulcers of < 1.0 cm)
Number of subjects: 120
Study 12492739 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor alone (for ulcers of < 1.0 cm)
Number of subjects: 120
Study 12492739 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (for ulcers of 1.0 to < 1.5 cm)
Number of subjects: 120
Study 12492739 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor alone (for ulcers of 1.0 to < 1.5 cm)
Number of subjects: 120
Study 12492739 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (for ulcers of > or = 1.5 cm)
Number of subjects: 120
Study 12492739 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor alone (for ulcers of > or = 1.5 cm)
Number of subjects: 120
Study 10865302 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (75, 150, or 225 mg/d)
Number of subjects: 251
Study 10865302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 9107153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 21
Study 9107153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 7902034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.9 mg/kg
Number of subjects: 50
Study 7902034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 1.2 mg/kg
Number of subjects: 50
Study 7902034 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.0 mg/kg
Number of subjects: 50
Study 7902034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg
Number of subjects: 50
Study 7902034 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg/kg
Number of subjects: 50
Study 7902034 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg/kg and 0.9 mg/kg
Number of subjects: 50
Study 3030619 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (mean dose: 29 g)
Number of subjects: 28
Study 3030619 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat bran (mean dose: 33 g)
Number of subjects: 28
Study 3030619 — intervention group
Group type: COMPARATOR
Intervention: Run-in period (white flour bread)
Number of subjects: 28
Study 29574039 — intervention group
Group type: EXPERIMENTAL
Intervention: E39 peptide vaccine (500 μg or 1000 μg)
Number of subjects: 0
Study 29574039 — intervention group
Group type: EXPERIMENTAL
Intervention: E39 followed by E39' (500 μg or 1000 μg)
Number of subjects: 0
Study 29574039 — intervention group
Group type: EXPERIMENTAL
Intervention: E39' followed by E39 (500 μg or 1000 μg)
Number of subjects: 0
Study 28723717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency localized muscle vibration (LMV) at 150 Hz using a commercial device VIBRA
Number of subjects: 30
Study 28723717 — intervention group
Group type: COMPARATOR
Intervention: Neuromuscular electrical stimulation
Number of subjects: 30
Study 26367306 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogy
Number of subjects: 0
Study 26367306 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit light (reduced informational load)
Number of subjects: 0
Study 26367306 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional explicit (large informational load)
Number of subjects: 0
Study 24028724 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA (group B)
Number of subjects: 264
Study 24028724 — intervention group
Group type: COMPARATOR
Intervention: TBNA (group A)
Number of subjects: 264
Study 24028724 — intervention group
Group type: COMPARATOR
Intervention: TBNA (group C1)
Number of subjects: 264
Study 24028724 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS‐TBNA (group C2)
Number of subjects: 264
Study 21933563 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 120
Study 21933563 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing care
Number of subjects: 120
Study 17641927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment
Number of subjects: 65
Study 17641927 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 65
Study 16611719 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) in patients with CKD
Number of subjects: 84
Study 16611719 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 84
Study 12958324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 30
Study 12958324 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 12958324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with retinopathy
Number of subjects: 30
Study 12958324 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus without retinopathy
Number of subjects: 30
Study 11010060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine 0.5% ophthalmic solution, instilled four times daily for 6 weeks
Number of subjects: 0
Study 11010060 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine 0.05%, instilled four times daily for 6 weeks
Number of subjects: 0
Study 11010060 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac tromethamine vehicle, instilled four times daily for 6 weeks
Number of subjects: 0
Study 8617884 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium with five escalating doses of up to 10(10) infectious units.
Number of subjects: 0
Study 8617884 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus vector encoding cystic fibrosis transmembrane conductance regulator, administered to the nasal epithelium.
Number of subjects: 0
Study 1306646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immune globulin (HDivIG) therapy at 500 mg/kg for a 2-hour period
Number of subjects: 32
Study 1306646 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment including phototherapy
Number of subjects: 32
Study 1306646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immune globulin (HDivIG) therapy
Number of subjects: 32
Study 6378236 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg four times daily for six weeks)
Number of subjects: 41
Study 6378236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 29361285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy (Simvastatin and Ezetimibe)
Number of subjects: 1873
Study 29361285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1873
Study 25710082 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression rate of 120 beats/min
Number of subjects: 38
Study 25710082 — intervention group
Group type: COMPARATOR
Intervention: Compression rate of 100 beats/min
Number of subjects: 38
Study 25710082 — intervention group
Group type: COMPARATOR
Intervention: Compression rate of 160 beats/min
Number of subjects: 38
Study 25728553 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical screws (CS)
Number of subjects: 79
Study 25728553 — intervention group
Group type: COMPARATOR
Intervention: Pedicle screws (PS)
Number of subjects: 79
Study 23981370 — intervention group
Group type: EXPERIMENTAL
Intervention: MMT+AA
Number of subjects: 97
Study 23981370 — intervention group
Group type: COMPARATOR
Intervention: MMT
Number of subjects: 97
Study 21043369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal gel (Prepidil)
Number of subjects: 151
Study 21043369 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal pessary (Propess)
Number of subjects: 151
Study 18668014 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 161
Study 18668014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 16563861 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-massage and skin care using a cream containing aromatherapy oils
Number of subjects: 0
Study 16563861 — intervention group
Group type: COMPARATOR
Intervention: Self-massage and skin care using a cream without aromatherapy oils
Number of subjects: 0
Study 14990779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 0
Study 11407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention to increase protein and energy intake
Number of subjects: 88
Study 11407868 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention group
Number of subjects: 88
Study 11407868 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 9406295 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (30 mg/kg intravenously)
Number of subjects: 16
Study 9406295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 16
Study 7956628 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention (TDI)
Number of subjects: 275
Study 3259683 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic spinal cord stimulation at optimal parameters for 2 months
Number of subjects: 8
Study 3259683 — intervention group
Group type: COMPARATOR
Intervention: Chronic spinal cord stimulation at placebo parameters for 2 months
Number of subjects: 8
Study 3259683 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall stimulation (both optimal and placebo)
Number of subjects: 8
Study 29776815 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon (QT) autograft
Number of subjects: 56
Study 29776815 — intervention group
Group type: COMPARATOR
Intervention: Hamstring tendon (HT) autograft
Number of subjects: 56
Study 29776815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HT and QT autografts
Number of subjects: 56
Study 26718578 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,400 IU cholecalciferol daily for 6 months
Number of subjects: 40
Study 26718578 — intervention group
Group type: COMPARATOR
Intervention: 800 IU cholecalciferol daily for 6 months
Number of subjects: 40
Study 24456999 — intervention group
Group type: EXPERIMENTAL
Intervention: Stand still …, and move on intervention
Number of subjects: 97
Study 22325594 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer delivered substance abuse and depression intervention
Number of subjects: 0
Study 22325594 — intervention group
Group type: COMPARATOR
Intervention: Computer-delivered typing tutorial
Number of subjects: 0
Study 20375930 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized alert advising general practitioners to discuss chlamydia testing
Number of subjects: 68
Study 20375930 — intervention group
Group type: COMPARATOR
Intervention: No alert (control group)
Number of subjects: 68
Study 17919763 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride 3mg (morning) and insulin glargine (bedtime) with dose titration
Number of subjects: 100
Study 15520831 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with 22q11DS
Number of subjects: 21
Study 15520831 — intervention group
Group type: COMPARATOR
Intervention: Sibling controls
Number of subjects: 21
Study 12593612 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic insertion of VP shunt
Number of subjects: 393
Study 12593612 — intervention group
Group type: COMPARATOR
Intervention: Nonendoscopic insertion of VP shunt
Number of subjects: 393
Study 10392329 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg and 10 mg, diltiazem 200 mg and 300 mg, mibefradil 50 mg and 100 mg
Number of subjects: 335
Study 10392329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (low dose)
Number of subjects: 335
Study 10392329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (high dose)
Number of subjects: 335
Study 10392329 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil
Number of subjects: 335
Study 8888913 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary iron intake
Number of subjects: 394
Study 8888913 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral iron therapy for adolescents with s-ferritin < 12 micrograms l-1
Number of subjects: 394
Study 8888913 — intervention group
Group type: COMPARATOR
Intervention: s-ferritin levels
Number of subjects: 394
Study 8888913 — intervention group
Group type: COMPARATOR
Intervention: s-ferritin and transferrin saturation correlation
Number of subjects: 394
Study 8888913 — intervention group
Group type: COMPARATOR
Intervention: Mean serum ferritin concentration
Number of subjects: 394
Study 1986667 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (400 micrograms twice daily)
Number of subjects: 16
Study 1986667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1986667 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 16
Study 6852361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (20 mg)
Number of subjects: 16
Study 6852361 — intervention group
Group type: COMPARATOR
Intervention: Codeine (20 mg)
Number of subjects: 16
Study 30753216 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred healthcare facility for chest pain
Number of subjects: 718
Study 30753216 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of cardiac causes of chest pain
Number of subjects: 718
Study 30753216 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in hospital preference
Number of subjects: 718
Study 29633583 — intervention group
Group type: EXPERIMENTAL
Intervention: Total steps·day‐1 at 18 months
Number of subjects: 260
Study 29633583 — intervention group
Group type: EXPERIMENTAL
Intervention: BOUT‐MVPA steps·day‐1 at 18 months
Number of subjects: 260
Study 27503018 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward system (Group B)
Number of subjects: 100
Study 27503018 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Group A)
Number of subjects: 100
Study 26035251 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine administration
Number of subjects: 34
Study 26035251 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside administration
Number of subjects: 34
Study 22412169 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese lacto-vegetarian diet
Number of subjects: 295
Study 22412169 — intervention group
Group type: COMPARATOR
Intervention: Omnivore diet
Number of subjects: 295
Study 20075385 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program (single 1- to 1.5-hour education session, action plan for self-treatment of exacerbations, monthly follow-up calls)
Number of subjects: 743
Study 20075385 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 743
Study 20075385 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management program
Number of subjects: 743
Study 18578170 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide solution (Opalescence)
Number of subjects: 96